Pluri Inc. develops cell-based technologies built around its proprietary 3D cell expansion platform. Company news commonly covers mass-scale cell expansion, biofarming, regenerative medicine applications, immune-cell manufacturing intellectual property, and the use of PluriCDMO™ for contract development and manufacturing programs involving cell-derived therapeutics, biologics, and placenta-derived biomaterials.
Recurring updates also address Pluri’s venture and subsidiary activity across foodtech, agtech, and health and aesthetics, including Coffeesai, Ever After Foods, Kokomodo, and Cellav. Additional news themes include commercial collaborations, patent grants, board and governance changes, private placements, and other capital actions tied to Pluri’s platform, subsidiaries, and public-company structure.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.